Orchard Therapeutics plc Debt to Equity

Orchard Therapeutics plc posts a debt-to-equity ratio of 0.61. That is above the Healthcare sector average of 0.27. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a debt-to-equity ratio near 0.27 is typical. Orchard Therapeutics plc's 0.61 is higher that level. That is roughly 127.9% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Orchard Therapeutics plc's debt-to-equity ratio of 0.61 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for ORTX's debt-to-equity ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 0.27), and (3) consistency with growth and profitability. This page covers the first two; Orchard Therapeutics plc's other metric pages and overview cover the third.

Judging Orchard Therapeutics plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in debt-to-equity ratio easier to interpret. Start with 0.61 here, then scan peer and history charts to see if the gap is persistent.